CareDx, Inc. (CDNA)
69.20
+2.12
(+3.16%)
USD |
NASDAQ |
Oct 20, 16:00
69.01
-0.19
(-0.27%)
After-Hours: 07:49
CareDx Research and Development Expense (TTM) : 79.87M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 79.87M |
| March 31, 2026 | 74.32M |
| December 31, 2025 | 71.43M |
| September 30, 2025 | 68.57M |
| June 30, 2025 | 69.29M |
| March 31, 2025 | 72.15M |
| December 31, 2024 | 72.34M |
| September 30, 2024 | 74.17M |
| June 30, 2024 | 75.68M |
| March 31, 2024 | 76.22M |
| December 31, 2023 | 81.87M |
| September 30, 2023 | 87.16M |
| June 30, 2023 | 90.47M |
| March 31, 2023 | 92.86M |
| December 31, 2022 | 90.39M |
| September 30, 2022 | 88.86M |
| June 30, 2022 | 86.00M |
| March 31, 2022 | 82.40M |
| December 31, 2021 | 76.52M |
| September 30, 2021 | 67.80M |
| June 30, 2021 | 60.84M |
| March 31, 2021 | 54.93M |
| December 31, 2020 | 48.94M |
| September 30, 2020 | 44.56M |
| June 30, 2020 | 40.61M |
| Date | Value |
|---|---|
| March 31, 2020 | 35.11M |
| December 31, 2019 | 30.71M |
| September 30, 2019 | 25.55M |
| June 30, 2019 | 20.89M |
| March 31, 2019 | 16.76M |
| December 31, 2018 | 14.51M |
| September 30, 2018 | 13.76M |
| June 30, 2018 | 12.85M |
| March 31, 2018 | 12.47M |
| December 31, 2017 | 12.39M |
| September 30, 2017 | 12.51M |
| June 30, 2017 | 12.48M |
| March 31, 2017 | 12.51M |
| December 31, 2016 | 12.39M |
| September 30, 2016 | 11.94M |
| June 30, 2016 | 11.70M |
| March 31, 2016 | 11.07M |
| December 31, 2015 | 9.333M |
| September 30, 2015 | 7.927M |
| June 30, 2015 | 6.265M |
| March 31, 2015 | 4.547M |
| December 31, 2014 | 3.846M |
| September 30, 2014 | 3.394M |
| June 30, 2014 | 3.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Natera, Inc. | 787.38M |
| Caris Life Sciences, Inc. | 117.14M |
| Myriad Genetics, Inc. | 105.80M |
| BioRestorative Therapies, Inc. | 9.374M |
| Exagen, Inc. | 6.466M |